accountBOSTON (MarketWatch) -- Shares of partners Johnson & Johnson and Bayer AG lost ground Tuesday ahead of a U.S. regulatory meeting called to consider their blood-thinner Xarelto. By constrast, biotech issues gained some momentum, with the Amex...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biotech Stocks: Biotech stocks gain; J&J, Bayer fall ahead of FDA meeting
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account